Cancer in Moldova

IARC estimates 11,349 new cancer cases and 6,141 cancer deaths in Moldova in 2024; the commonest new cancers are colorectum, breast and trachea, bronchus and lung. This page is assembled automatically from OnCo's data: 22 trials with a site there, 1 institution and 1 person, and says what OnCo does not yet hold.

Cancer figures, GLOBOCAN 2024

Compare countries →

New cases

11,349

all cancers

Deaths

6,141

all cancers

Incidence rate

225.4

per 100,000, age-standardised

Mortality rate

111.0

per 100,000, age-standardised

Cumulative risk

23.3%

of a cancer by age 74

Population

3,034,966

IARC, 2024

Built partly from other countries' data. IARC's method code for Moldova's incidence estimate is 3b: national mortality estimates applied to model-based mortality-to-incidence ratios (neighbouring country registry data). Read the figures as a regional estimate, not a count.

Most new cases

Site	New cases	Rate	OnCo page
Colorectum	1,785	32.0	Colorectal cancer
Breast	1,459	53.1	Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer, HER2-positive breast cancer
Trachea, bronchus and lung	1,025	19.4	Lung cancer (all types), Non-small-cell lung cancer, Small-cell lung cancer
Prostate	909	38.2	Prostate cancer
Stomach	499	9.1	Gastric & gastro-oesophageal junction cancer
Corpus uteri	498	17.0	Endometrial cancer
Bladder	461	8.1	Bladder & urothelial cancer
Cervix uteri	440	19.9	Cervical cancer
Liver and intrahepatic bile ducts	433	8.0	Hepatocellular carcinoma
Pancreas	383	7.0	Pancreatic ductal adenocarcinoma

Most deaths

Site	Deaths	Rate	OnCo page
Trachea, bronchus and lung	959	17.4	Lung cancer (all types), Non-small-cell lung cancer, Small-cell lung cancer
Colorectum	935	15.6	Colorectal cancer
Breast	516	15.9	Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer, HER2-positive breast cancer
Stomach	422	7.4	Gastric & gastro-oesophageal junction cancer
Liver and intrahepatic bile ducts	414	7.5	Hepatocellular carcinoma
Pancreas	371	6.5	Pancreatic ductal adenocarcinoma
Prostate	298	12.7	Prostate cancer
Brain, central nervous system	179	3.9	Glioma & glioblastoma
Cervix uteri	177	6.6	Cervical cancer
Bladder	172	2.7	Bladder & urothelial cancer

Incidence: method 3b, national mortality estimates applied to model-based mortality-to-incidence ratios (neighbouring country registry data).
Mortality: method 1, trends in national rates projected to 2024.
Rates are age-standardised per 100,000 (World standard population), both sexes, all ages. Non-melanoma skin cancer is left out of the site lists, as on the deep dives. IARC lists the country as “Republic of Moldova”, in Eastern Europe (Europe), High HDI, upper middle income.
Source: Ervik M, Laversanne M, Lam F, Colombet M, Ferlay J, Filho AM, Bray F (2026). Global Cancer Observatory: Cancer Today (2024 estimates, version 1.0). Lyon, France: International Agency for Research on Cancer. https://gco.iarc.who.int/today, read through the IARC API on 2026-11-04.

Trials with a site here

22 trials in OnCo · 11 recruiting overall

22 trials

Trial			Lead sponsor
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies NCT05006716	Phase 1/2	Recruiting	BeOne Medicines	114	2026-10-05
A Platform Study in Non-Small Cell Lung Cancer (NSCLC) NCT06996782	Phase 1/2	Recruiting	AstraZeneca	103	2026-10-01
AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2 NCT06219941	Phase 2	Recruiting	AstraZeneca	52	2026-09-30
DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment NCT07472517	Phase 3	Recruiting	Boehringer Ingelheim	245	2026-09-29
A Study to Assess Safety and Efficacy of SOT109 in Patients With Advanced Unresectable or Metastatic Colorectal Cancer NCT07693751	Phase 1/2	Recruiting	SOTIO Biotech a.s.	3	2026-09-21
A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer NCT06827236	Phase 1/2	Recruiting	BioNTech SE	79	2026-09-17
A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced NCT07111520	Phase 1/2	Recruiting	BioNTech SE	85	2026-08-05
A Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell Cancers NCT05910827	Phase 1/2	Recruiting	Hummingbird Bioscience	20	2026-05-27
A TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND EFFICACY OF SHR-A1904 IN SUBJECTS WITH ADVANCED SOLID TUMORS NCT05277168	Phase 1/2	Recruiting	Jiangsu HengRui Medicine Co., Ltd.	28	2026-05-22
A Phase 1/2 Study to Investigate CRB-701 in Solid Tumors NCT06265727	Phase 1/2	Recruiting	Corbus Pharmaceuticals Inc.	41	2026-01-08
Namodenoson in the Treatment of Advanced Hepatocellular Carcinoma in Patients With Child-Pugh Class B7 Cirrhosis NCT05201404	Phase 3	Recruiting	Can-Fite BioPharma	32	2025-04-29
Modular Clinical Pharmacology Study to Evaluate the Drug-drug Interaction Potential and Relative Bioavailability of Saruparib NCT06899061	Phase 1	Active not recruiting	AstraZeneca	4	2026-10-01
An Efficacy and Safety Study of Erdafitinib (JNJ-42756493) in Participants With Urothelial Cancer NCT02365597	Phase 2	Active not recruiting	Janssen Research & Development, LLC	105	2026-09-25
A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study NCT02960022	Phase 2	Active not recruiting	Astellas Pharma Global Development, Inc.	234	2026-09-11
A Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB12 (Proposed Pembrolizumab Biosimilar) to Keytruda® in Non-small Cell L NCT06687369	Phase 3	Active not recruiting	mAbxience Research S.L.	173	2026-09-10
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, in Participants With Advanced Cancers NCT02908906	Phase 1/2	Active not recruiting	Janssen Research & Development, LLC	20	2026-08-31
GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors NCT04083599	Phase 1/2	Active not recruiting	Genmab	76	2026-08-04
A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC NCT04995523	Phase 1/2	Active not recruiting	AstraZeneca	40	2026-07-14
A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer NCT05635708	Phase 2	Active not recruiting	BeiGene	61	2026-04-15
A Study to Evaluate ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Unresectable or Metastatic Melanoma NCT06054555	Phase 3	Active not recruiting	Amgen	180	2026-01-12
A Study to Assess the Safety and Efficacy of AZD7789 in Participants With Advanced or Metastatic Solid Cancer NCT04931654	Phase 1/2	Active not recruiting	AstraZeneca	21	2025-10-09
Drug-drug Interaction Study With AZD5305 and Itraconazole in Patients With Advanced Solid Malignancies NCT05573724	Phase 1	Completed	AstraZeneca	2	2024-06-18

Trial records in OnCo whose ClinicalTrials.gov entry lists at least one site in Moldova, captured 2026-10-07 to 2026-10-08. Recruiting first, then the most recently updated. The status is the study's overall status; whether a site in Moldova is open is on the registry page, under Contacts and Locations.

Institutions, companies and people

1 institution

Oncological Institute of Moldova

1 person

People whose main affiliation in OnCo is an institution or company in Moldova.

Ruslan Baltaga

Approvals

OnCo records approvals for United States, European Union, United Kingdom, Japan, China, Australia and India. Moldova is not one of them, so no approval in OnCo speaks for it. See the approvals by region matrix for what is held.

What OnCo does not yet hold

No registry figures. The figures above are IARC's estimates; OnCo has not read Moldova's own cancer registry, its survival figures or its stage at diagnosis.
No payer detail: who pays for cancer care in Moldova, what a patient pays, and which medicines are reimbursed.
No regulator detail: the national medicines regulator, its approval routes and its decisions.
No national cancer plan, guideline, screening schedule or treatment-centre list read from Moldova's own sources.

Moldova is not among the 60 countries ranked in the country coverage queue (November 2026), which ranks countries without a page by cases, deaths, research output and population. Know a source? Suggest an edit.

Sources and machine-readable data

IARC Global Cancer Observatory, GLOBOCAN 2024: Cancer Today.
ClinicalTrials.gov study records, courtesy of the US National Library of Medicine, as captured in each trial record.
OnCo records: each chip and card opens a record with its own sources.
This page as JSON: /api/v1/countries/md.json; every country: /api/v1/countries.json.